Table 3.

End points of the EMPA-REG OUTCOME Trial

Outcome	Hazard Ratio Compared with Placebo (95% CI)
Prespecified
Primary MACE (CV death, nonfatal MI, or nonfatal stroke)	0.86 (0.74 to 0.99)
CV death	0.62 (0.49 to 0.77)
All-cause mortality	0.68 (0.57 to 0.82)
Hospitalization for heart failure	0.65 (0.50 to 0.85)
Exploratory
New onset of macroalbuminuria	0.62 (0.54 to 0.72)
New onset or worsening of DKD	0.61 (0.53 to 0.70)
Doubling of serum creatininea	0.56 (0.39 to 0.79)
Initiation of RRT	0.45 (0.21 to 0.97)

Created with data from the supplemental appendix of the Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empaglifozin (EMPA-REG OUTCOME) (5,6). At baseline, the study population had an average eGFR of approximately 74 ml/min per 1.73 m². 95% CI, 95% confidence interval; MACE, major adverse cardiovascular event; CV, cardiovascular; MI, myocardial infarction; DKD, diabetic kidney disease.

^aAccompanied by eGFR≤45 ml/min per 1.73 m².